Innovalve Bio Medical News
2 articles
growth-positive
Edwards Lifesciences buys Israeli co Innovalve Bio Medical
Edwards Lifesciences has announced its intention to acquire Israeli medical device company Innovalve Bio Medical. While no financial details were disclosed, the acquisition is estimated to be worth hundreds of millions of dollars. Innovalve, which was founded at Sheba Medical Center, has previously signed a technology agreement with Edwards Lifesciences. The acquisition will enhance Edwards trans-catheter mitral valve replacement technologies and support its long-term growth. Innovalve will join Edwards trans-catheter mitral and tricuspid therapies product group.
AcquisitionExpand
growth-positive
ALIVE Fund leads financing round for mitral heart valve maker Innovalve
ALIVE, a healthtech venture capital fund, has made its first investment of $10.5 million in Innovalve Bio Medical Ltd., a company developing technology in the field of cardiology. ALIVE recently secured $150 million from various investors. Innovalve has developed an artificial mitral valve for treating heart disease and is seeking FDA approval for human trials. The ALIVE Fund focuses on investing in late-stage medical device and IT companies. ALIVEs advantage lies in its team of experienced professionals, cooperation agreements with medical centers, and its focus on medical device companies. Israel is seen as a hub for medical companies due to its entrepreneurial advantage and lower development costs compared to Silicon Valley.
InvestmentPartners
